S100A8 and juvenile idiopathic arthritis: Biomarker performance with or without concurrent MTX therapy. Generally, at month 3, lower baseline S100A8/9 levels were associated with numerically higher odds of achieving JIA-ACR ID in patients receiving abatacept with MTX compared with patients receiving abatacept alone (Supplementary Table 6); a similar relationship was observed for S100A12.